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Defects in chromatin proteins frequently manifest in diseases. A striking case of a chroma-
tin-centric disease is NUT-midline carcinoma (NMC), which is characterized by expression
of NUT as a fusion partner most frequently with BRD4. ChIP-sequencing studies from NMC
patients revealed that BRD4-NUT (B4N) covers large genomic regions and elevates tran-
scription within these domains. To investigate how B4N modulates chromatin, we per-
formed affinity purification of B4N when ectopically expressed in 293-TREx cells and
quantified the associated histone posttranslational modifications (PTM) using proteomics.
We observed significant enrichment of acetylation particularly on H3 K18 and of combinato-
rial patterns such as H3 K27 acetylation paired with K36 methylation. We postulate that
B4N complexes override the preexisting histone code with new PTM patterns that reflect
aberrant transcription and that epigenetically modulate the nucleosome environment
toward the NMC state.
Introduction
Histones assemble genomic DNA into chromatin and display many posttranslational modifi-
cations (PTMs) such as lysine acetylation. Nearly all PTMs are enzymatically regulated, for
instance by lysine acetyltransferases (KATs) such as EP300. In addition PTMs can also be rec-
ognized by other non-histone proteins containing specific domains, for instance by bromodo-
main proteins such as BRD4. Many of these factors themselves regulate gene expression [1].
Consequently defects in the orchestration between enzymes and binding proteins can disrupt
chromatin PTMs and the underlying transcriptional patterns, potentially manifesting in dis-
ease [2].
NUT-midline carcinomas (NMCs) are aggressive squamous cell cancers observed across a
wide age distribution and are characterized by somatic expression of theNUT gene (also anno-
tated as NUTM1), which is normally restricted to the germline [3]. Expression of the otherwise
silent NUT gene arises from an in-frame fusion with an actively transcribed gene, most
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commonly with BRD4 to yield BRD4-NUT (B4N). Remarkably B4Nmaps to approximately
one hundred chromatin domains ranging from 100 to 2000 kilobases termed ‘megadomains’
that span genic and intergenic regions and that dwarf the 1 to 10 kilobase-sizeddomains occu-
pied by most regulatory factors, for instance wild-type BRD4 [4].
How megadomains lead to the NMC pathology remains unclear. It has been hypothesized
that in the process of creating these unusual structures B4N complexes ectopically regulate
expression of key oncogenes, such as SOX2, MYC and TP63, though histone acetylation [5, 6].
ChIP-sequencing (ChIP-seq) has revealed that B4N co-localizeswith histone H3 K27 acetyla-
tion (H3K27ac) in NMC cells, and additionally, when B4N is induced in non-NMC 293-TREx
cells, the spreading of B4N coincides temporally and spatially with the spreading of H3K27ac
[4]. The link betweenB4N and acetylation reflects both the bromodomain recognition of acety-
lated lysines and the NUT interaction with EP300 [6]. Indeed, when the NUTmodule alone is
fused to a LacI binding domain and expressed in cells with a LacO-containing reporter, NUT
alone is sufficient to concentrate high levels of H4 acetylation at the transgenic locus [7].
In contrast to antibodies directed against individual PTMs, liquid chromatography-mass
spectrometry (LC-MS) can characterize a broader and more complex array of PTMs without
complications such as epitope occlusion. Here we applied LC-MS based proteomics to charac-
terize the histone PTMs that co-purify with B4N when ectopically expressed and crosslinked
on chromatin in 293-TREx cells.We chose to perform our studies in these cells in order to sim-
ulate the expression of B4N in a negative megadomain background, similar to the presumptive
initial NMC stages. As a positive control, we expressed wild type BRD4 (short form, 722 resi-
dues in length, hereafter abbreviated as BRD4short) which shares the same double bromodo-
mains as B4N. In terms of amino acid sequence, BRD4-NUT is essentially BRD4short fused to
the full length NUT. As a negative control, we expressed L3MBTL3 which lacks bromodo-
mains, maintains Polycomb group gene repression and is functionally unrelated to B4N.We
crosslinked cells and performed affinity pulldowns to enrich for each bait-associated complex
for proteomic analysis.
We expected to recover at minimum a similar level of histone acetylation from both the
B4N and BRD4short pulldowns. In fact we found that B4N uniquely enriches for hyper-acety-
lated and combinatorially modified histones distinct from BRD4short. Some of these combina-
tions are comprised of PTMs that are rarely observed to co-localize or overlap together. We
propose that the mechanisms of gene regulation by B4N are significantly different from
BRD4short, namely that the B4N complex directly overrides the pre-existing histone PTM pat-
terns, forming aberrant patterns that correspond to aberrant transcription linked to oncogene-
sis. The proteomic characterizations of PTMs found within B4Nmegadomains will serve as an
invaluable resource for future NMC research.
Materials and Methods
Cloning/Tissue Culture
The 293-TREx-NBioTAP-BRD4NUT cell line was generated as described in our previous
report [4]. The 293-TREx-NBioTAP-BRD4short cell line was generated by FRT recombination
with the plasmid pcDNA5 FRT/TO/N-BioTAP BRD4. To generate the pcDNA N-terminal
BioTAP BRD4 plasmid itself, we used the Gateway recombination system to introduce the
BRD4 cDNA clone (CSBHuman Orfeome Collection; Internal ID: 71377) into pcDNA5 FRT/
TO/NBioTAP vector. The 293-TRex-NBioTAP-L3MBTL3 cell line was generated by lentiviral
infectionwith the pHAGE-NBioTAP L3MBTL3 plasmid. To generate the pHAGE N-terminal
BioTAP L3MBTL3 plasmid itself, we used the Gateway recombination system to introduce the
L3MBTL3 cDNA clone (CSBHuman Orfeome Collection; Internal ID: 10868) into pHAGE
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NBioTAP vector. All cell lines were cultured in DulbeccoModified EagleMedium (Invitrogen)
supplemented with 10% (v/v) fetal bovine serum (Atlanta Biologicals) and 1% (v/v) GlutaMAX
(Invitrogen) and grown in a humidified incubator (Thermo Fisher) set at 37°C and 5% CO2.
BioTAP-XL and LC-MS
Ten 15cm plates of 293-TREx cells containing expression cassettes for BioTAP-tagged
BRD4short, L3MBTL3, and BRD4-NUTwere induced by doxycycline at a concentration of
1 μg/ml overnight. Following induction, cells were processed to isolate the histones associated
with the tagged baits as previously described [8]. Histones were derivatized with propionic
anhydride both before and after trypsin digestion prior to desalting by in-lab constructedC18
STAGE-tips (3M). Desalted peptides were lyophilized by vacuum centrifuge and stored in
-20°C. Peptides were re-suspended in HPLC buffer A (2.5% v/v acetonitrile, 0.1% formic acid,
97.4% water) and analyzed on an LTQ-Velos Orbitrap mass spectrometer (Thermo Fisher).
Samples were autosampler loaded (FAMOS, LC Packings) onto C18 (reversed phase columns
(Accucore 2.6 μm particle size, Thermo Fisher) heated to 60°C and electrosprayed into a Velos
Orbitrap-Ion Trap (Thermo Fisher) mass spectrometer for analysis. MS data can be found at:
https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/6UMRIP.
In order to compare the relative levels of histone PTMs between the BioTAP-XL pulldown
and genomic input, we first tested if both pulldown and input PTM data were normally distrib-
uted using the Shapiro-Wilk test. If data were normally distributed, we compared the change in
PTM levels between pulldown and input using unpaired two-sample Welch’s t-test, which
does not assume equal variance between the samples. All statistical tests were conducted using
the respective built-in functions in the R software package (version 3.2.2, The R Foundation).
Histone PTM levels are provided in S1 Table.
Total cellular histones were extracted as described in an earlier report [8]. Cells were lysed
in Nuclear Extraction Buffer (20mMHEPES pH 7.6, 10% sucrose, 10mMNaCl, 3mMMgCl2,
0.2% Triton X-100, 1mM PMSF), followed by TEN400 buffer wash (10mM TrisCl pH 8.0,
1mM EDTA, 400mMNaCl, 1mM PMSF). Chromatin was extracted with TEN2000 buffer
(10mMTrisCl pH 8.0, 1mM EDTA, 2MNaCl, 1mM PMSF), followed by acidificationwith sul-
furic acid. The histones in the supernatant were precipitated with trichloracetic acid, washed
with acetone, and re-suspended in 100mM ammonium bicarbonate (pH = 8.0).
For Western Blotting, the BioTAP-tagged baits were induced overnight with tetracycline.
Cells were scraped and washed in Dulbecco’s Phosphate Buffered Saline (Boston BioProducts,
1mM PMSF) prior to lysis in RIPA buffer (140mMNaCl, 10mM TrisCl pH 8.0, 1mM EDTA,
1% Triton X-100, 0.1% SDS, 1mM PMSF) rotating for 15 minutes at 4°C. Supernatant was col-
lected and protein concentration was approximated with Bradford reagent (Bio-Rad) using 595
nm absorbance. Approximately 60 micrograms of protein extract from each cell line were
loaded per well on a TruPAGE 4–20% gradient gel (Sigma Aldrich). BioTAP-tagged baits were
probed with peroxidase anti-peroxidase complex (1:1000 v:v, PAP, Sigma Aldrich, catalog
number P1291) and loading control was determinedwith anti-GAPDH antibody (1:4000 v:v,
Ambion, catalog number AM4300) and secondaryHRP-conjugated anti-mouse antibody
(1:4000 v:v, GE Healthcare, catalog number NA931). Chemiluminescencewas detectedwith
Clarity™Western ECL Substrate (Bio-Rad) using an Odyssey FC Imager (Licor). Membrane
was stained with Ponceau Red (Boston Bioproducts) to visualize total proteins.
Imaging
293-TREx cells were grown on coverslips in a 6-well plate (Celltreat). HA- BRD4short isoform
or HA-B4N were induced by incubating cells overnight at 37°C in media containing 1 μg/mL
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tetracycline. Cells were fixed in 4% paraformaldehyde for 10 minutes at room temperature,
then permeabilized in 0.3% Triton X-100 for 5 minutes at room temperature. Cells were then
incubated in blocking buffer (PBS containing 0.3% Triton X-100 and 5%milk) for 30 minutes
at room temperature. Cells were then incubated in primary antibody for 1 hour at room tem-
perature. After washing in PBS, cells were incubated in secondary antibody for 1 hour at room
temperature. Cells were washed in PBS and nuclei were counterstained with ProLong Gold
anti-fade reagent with 4’,6-diamino-2-phenylindole (DAPI) (Life Technologies, catalog num-
ber P36935). Primary antibodies used were anti-HA.11 epitope tag (1:1000 v:v, BioLegend, cat-
alog number 901513), anti-H3K18ac (1:1000 v:v, Abcam, catalog number ab1191). Secondary
antibodies included goat anti-mouse Alexa fluor 488 and goat anti-rabbit Alexa fluor 594
(1:1000 v:v, Life Technologies, catalog numbers A-11001 and A-11012). All antibodies were
diluted in PBS containing 0.3% Triton X-100 and 5%milk. Images were acquired on an AxioS-
kop2 mot plus (Zeiss) fluorescencemicroscope and processed with Axiovision software (Zeiss
Release 4.8).
Colocalization images were acquired by confocal microscopy. Confocal images were
acquired on a Zeiss LSM 510 microscope using a 488nm, 543nm and multi-photon excitation
at 780nm for the green, red and blue emitting fluorophores respectively; emission filters are
band pass filters in the range of 500-530nm, 565-615nm, and 435-485nm. The objective is a
Zeiss Plan-Apochromat 62x/1.4NA.
Results
Use of BioTAP-XL to identify chromatin factor associated histone PTMs
We previously described the application of crosslinking and proteomics to analyze the histone
PTMs associated with chromatin factors fused to the BioTAP affinity tag (Fig 1) [8]. While any
tag could disrupt protein function, we demonstrated previously that BioTAP-B4N binds to the
same genomic regions as endogenous un-tagged B4N in NMC patient cells by ChIP-seq [4].
Furthermore tagged B4N when expressed in 293-TREx cells forms a similar number of mega-
domains as seen in NMC cells, albeit in cell-type specific regions. As B4N also forms cell type-
specificmegadomains in different patients, this localization provides additional evidence that
the BioTAP-tagged B4N functions similarly as the normally observeduntagged oncoprotein,
Fig 1. Experimental design to determine complex-specific histone PTMs. The BioTAP affinity tag, which combines
both Protein A and a biotinylation acceptor sequence, was cloned into the N-terminus of the three different cDNAs. Tissue
culture cells expressing the tagged baits were crosslinked with formaldehyde and sonicated prior to affinity pulldowns and
on-bead derivatization.
doi:10.1371/journal.pone.0163820.g001
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and that 293-TREx cells are a suitable system for studying the initial events in megadomain for-
mation [4].
We generated 293-TREx cell lines expressing inducible BioTAP-L3MBTL3, BioTAP-BRD4-
short, and BioTAP-B4N (S1 Fig) [4]. After we induced bait expression, we crosslinked nuclei
with formaldehyde and sonicated the chromatin suspension.We then performed affinity pull-
downs of the tagged complex using IgG-agarose to bind the Protein A epitope in the first step,
followed by streptavidin-agarose to bind the biotinylated tag in the second step. Finally we
derivatized the streptavidin-bound complexes prior to trypsin digestion to release histone pep-
tides of sufficient hydrophobicity and reduced charge state for reversed phase LC-MS.
To determine the enriched histone PTMs, we performed label-free relative quantification of
the various modified peptides.We integrated the chromatographic peaks of each peptide and
normalized the area against all modified forms of the same peptide backbone. This method of
quantification differs from spectral counting, which measures the total number of MS/MS col-
lected. If our baits did not enrich for specific histone PTM patterns, we would expect to recover
essentially background levels of PTMs that are of a similar relative distribution as the genomic
input. For certain peptides such as the mono-acetylatedH3 18–26 peptide (K18QLATK23AAR),
where the single acetyl group can localize to either K18 or K23 and where these two isoforms
can co-elute, we additionally relied on MS/MS quantification.We examined the average MS/
MS across the chromatographic peak and determined the relative fragment ion ratios charac-
teristic of either isoform.
Our experimental variability can be approximated by how consistently we recover peptides
expected to be equally present across our samples. Most human canonical H2A histones, such
as type 1-B/E and 2-A, contain either a threonine or serine at position 16. Assuming this substi-
tution is indiscernible by our baits, we should recover peptides spanning the T16/S16 position
(AKAKT16R and AKAKS16R) at a consistent frequency. We observed that the fold difference
in the T16/S16 peptide levels did not differ by more than 20% of the sample mean value (S2
Fig). When interpreting our data, fold changes greater than double this threshold (that is, 0.4
times) are unlikely due to expected technical variability.
We next tested whether the expression of B4Nmight alter global histone PTM levels that
consequently would skew the results, similar to the effects of adding a pan-deacetylase inhibi-
tor. We extracted total cellular histones from 293-TREx cells before and after B4N induction
and quantified the PTM levels. Aside from a decrease in H3K79 di-methylation (me2) and tri-
methylation (me3) upon induction,most PTMs remain unchanged (S3 Fig). Thus, PTMs
enriched by B4N at greater than 0.4× fold of the control pulldowns are unlikely to be due to
global effects.
BRD4-NUT bound histones have overall distinct PTMs from BRD4short
bound histones
To understand how different the overall histone PTM patterns recovered from the B4N pulldown
are with respect to the other samples, we determined the Pearson correlation coefficient r for
pairwise comparisons between the samples. We find that histone PTMs of replicates are linearly
correlated with one another, while B4N histone PTM patterns are significantly non-correlated
with genomic or BRD4short PTM patterns (S4 Fig). Thus the B4N-associated histone PTM pat-
terns when considered collectively are distinct from BRD4short or input genomic PTM patterns.
BRD4-NUT complex drives H3K18 toward the acetylated state
To identify specific PTMs enriched by our baits, we first analyzed the H3 18–26 peptide span-
ning K18 and K23. EP300 and CREBBP are the main enzymes that acetylate K18 and K23 [9].
Histone PTM Activation by BRD4-NUT
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We found that pulldown of BRD4short significantly enriched for di-acetylatedH3K18acK23ac
relative to input (Welch: t = -21.19, df = 3.7172, p = 5.1×10−5; Shapiro-Wilk: genomic p = 0.44,
BRD4short genomic p = 0.95). Although B4N did not enrich for mono-acetylation relative to
the other baits, B4N did enriched for di-acetylationmore than 8-fold over BRD4short (Fig 2A).
To determine whether a particularmono-acetyl isoform was depleted, we resolved the mono-
acetylated peak into K18ac1 and K23ac1 (Fig 2B). Genomic levels of K23 mono-acetylation gen-
erally exceed K18 mono-acetylation in human tissue culture lines [10]. The K23ac majority is
reflected in the BRD4 and L3MBTL3 pulldowns. Our data suggest that B4N initially recognizes
histones mono-acetylated at K23 in a potentially similar manner as wild-type BRD4. The B4N
complex, and more specifically the EP300/CREBBP binding partner, would acetylate the next
available unmodified residue at K18 and convert the mono-acetylated K18unK23ac state into
the di-acetylated K18acK23ac state. We do not expect a similar enrichment for di-acetylation
with wild type BRD4, which exhibits no significant interaction with EP300.
The proteomic data suggest that B4N enriches for H3 K18 acetylation by driving local chro-
matin towards a hyper-acetylated state. As this was not a modification that we assayed in our
previous candidate approach, we induced BRD4short and B4N with a FLAG-HA tag in
293-TREx lines and assayed the localization of H3K18ac. If B4N-dependent PTM conversion
were occurring,we expected to detect a significant change in K18 acetylation patterns upon
B4N expression but not BRD4 expression. We found that in the non-induced state, endoge-
nous H3K18ac is distributed throughout the nucleus (S5 Fig). When wild type BRD4short is
induced, H3K18ac remains diffuse throughout the nucleus with low levels of granularity (Fig 3,
S5 Fig). In contrast, when B4N is induced, H3K18ac forms large foci that resemble NMCmega-
domains not seen when BRD4short is expressed (Fig 3, S5 and S6 Figs). We observed co-locali-
zation between the large H3K18ac foci and B4N (Fig 3). Thus the proteomic and microscopy
Fig 2. Quantification of H3 K18 and K23 acetylation enrichment. (A) Relative levels of unmodified, mono-acetylation, and di-acetylation of the H3
peptide spanning K18 and K23 in genomic and immunoprecipitated histones. Note that the mono-acetylation values combine K18ac1K23un and
K18unK23ac1 together. Error bars of genomic and BRD4short samples represent standard deviation of 4 replicates. Error bars of B4N sample represent
range of 2 replicates. Asterisk denotes significant difference in ac2 levels between input and BRD4short (p < 0.05). (B) Resolving the mono-acetylation
patterns in Fig 2A into the two isoforms for each sample. Relative levels are provided below each bar corresponding to K18ac1 (top bold) and K23ac1
(bottom) and are the same scale as in panel A. For instance, the 30% H3K23ac1 in the genomic sample is relative to unmodified, H3K18ac1, and
H3K18K23ac2 as seen in Panel A. Note that most of the mono-acetylated in the samples is K23ac1. 293 refers to genomic histones, L3 refers to
L3MBTL3 associated histones, and B4 refers to BRD4short associated histones.
doi:10.1371/journal.pone.0163820.g002
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experiments support a model where the B4N oncoprotein dramatically transforms histone
acetylation patterns within nuclear foci that were previously revealed to comprise the NMC
megadomains [4].
BRD4-NUT complex associates with hyper-acetylated H4
Like histone H3, histone H4 can also be extensively acetylated. Aside from N-terminal acetyla-
tion, H4 can be mono-, di-, tri-, and tetra-acetylated at K5, K8, K12, and K16. H4 acetylation is
broadly correlated with active transcription in a variety of organisms, with the notable excep-
tion that H4K12ac localizes over heterochromatin in fruit flies and budding yeast [11]. Interest-
ingly acetylation at these distinct residues have distinct metagene distributions. For instance
in mouse ES cells, H4K16ac is strongly enriched within a few kilobases both upstream and
downstream of transcriptional start sites while H4K8ac is more modestly enriched. H4K5ac is
relatively depleted at these sites [12]. To further illustrate the differences between the H4 acety-
lation residues, H4K5ac and H4K8ac are both enriched in non-small cell lung cancers that
include squamous cell carcinomas and adenocarcinomas compared to normal lung paren-
chyma, while H4K12ac and H4K16ac are depleted in the same cancers [13].
We quantified the acetyl states of the H4 4–17 peptide (GK5GGK8GLGK12GGAK16R) that
spans K5, K8, K12, and K16 from the pulldowns. BRD4short significantly enriched for H4 tri-
acetylation (Welch: t = -46.967, df = 5.1112, p = 6.2×10−8; Shapiro-Wilk: genomic p = 0.14,
BRD4short p = 0.78) and tetra-acetylation (Welch: t = -48.88, df = 3.0628, p = 1.5×10−5;
Fig 3. Formation of nuclear foci enriched in H3K18 acetylation by B4N and not BRD4short. Confocal microscopy of 293-TREx cells with
inducible HA-B4N and HA-BRD4short stained with anti-HA (green), which labels the bait protein, and anti-H3K18ac (red). Scale bar represents 10
micrometers. Zoomed-in images are provided to illustrate difference between H3K18ac granules in BRD4short cells and larger H3K18ac foci in B4N
cells. See S5 Fig for non-confocal imaging and S6 Fig for separate green and red confocal layers of the same wide-field image of B4N-expressing
cells.
doi:10.1371/journal.pone.0163820.g003
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Shapiro-Wilk: genomic p = 0.19, BRD4short p = 0.87) relative to input (Fig 4A). Strikingly B4N
enriched for both H4 tri- and tetra-acetylation to an even greater extent than BRD4short relative
to input, such that over half of the histone H4 recovered by B4N were either tri- or tetra-acety-
lated (Fig 4A). To interrogate whether B4N was preferentially associating with specific acety-
lated residues, we resolved the H4 tri-acetylated data into the four individual isoforms: K5/K8/
K12ac3, K5/K8/K16ac3, K5/K12/K16ac3, and K8/K12/K16ac3 (Fig 4B). We observed far greater
enrichment of the K5/K8/K12ac3 and the K5/K8/K16ac3 isoforms by B4N than either BRD4short
or L3MBTL3.
A common feature of both isoforms is acetylation at K5 and K8. Since the double bromodo-
mains of B4N are identical to wild type BRD4short, we predict that the intrinsic acetyl lysine
specificity of B4N is similar to wild type BRD4short. Other groups have performed in vitro pep-
tide binding assays showing that the individual bromodomains of BRD4 bind preferentially to
K5 acetylation [14]. The same assays also revealed that the EP300 bromodomain recognizes
K5ac, K8ac, and K12ac, but not K16ac. Consistent with these in vitro findings, in vivo imaging
experiments from other groups revealed significant co-localization betweenK5ac and K12ac
with CREBBP and betweenK8ac with EP300. Little co-localizationwas observedbetweenK16ac
with either KAT [15]. Thus the enrichment for H4 isoforms containing K5 and K8 acetylation
as measured by our experimentsmay reflect the selectivity of B4N interactors as well as B4N
itself.
BRD4-NUT complex enriches for K27 acetylation and K36 methylation
in the H3.3 variant
We demonstrated that B4N significantly enriches for H3K18 and K23 acetylation, as well as
H4K5 and K8 acetylation relative to control pulldowns in 293-TREx cells. We also examined
acetylation on the H3 9–17 peptide (K9STGGK14APR) spanning K9 and K14. We found that
Fig 4. Quantification of H4 K5, K8, K12, and K16 acetylation enrichment. (A) Relative levels of unmodified, mono-acetylation, di-acetylation, tri-
acetylation, and tetra-acetylation of the H4 peptide spanning K5, K8, K12, and K16 in genomic and immunoprecipitated histones. Error bars of
genomic and BRD4short samples represent standard deviation of 4 replicates. Error bar of B4N sample represents range of 2 replicates. Asterisks
denote significant difference in ac3 and ac4 levels between input and BRD4short (p < 0.05). (B) Resolving the tri-acetylation patterns in Fig 4A into the
four isoforms for each sample. The two most abundant tri-acetylated isoforms in the B4N samples are K5K8K12ac3 and K5K8K16ac3. Abbreviations
are the same as in Fig 2B.
doi:10.1371/journal.pone.0163820.g004
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BRD4short significantly enriched for di-acetylatedH3K9acK14ac over input (Welch: t = -13.162,
df = 3.0392, p = 8.9×10−4; Shapiro-Wilk: genomic p = 0.10, BRD4short p = 0.72). Additionally
we found that B4N enriches for di-acetylation at both H3 K9 and K14 by 2-fold over BRD4short
(S7 Fig). These results support a model where B4N recognizes and generates histone hyper-
acetylation at large genomic regions.
We next wanted to study how B4N might alter methylation by investigating the methyla-
tions on the H3 73–83 peptide (EIAQDFK79TDLR) spanning K79. We found that BRD4short
significantly enriched for H3K79 mono-methylation over input (Welch: t = -4.5686,
df = 2.6545, p = 0.02552; Shapiro-Wilk: genomic p = 0.15, BRD4short p = 0.53). We
found that B4N enriched for K79me1, but not K79me2 (S8 Fig), to a greater extent over
BRD4short. The lack of K79me2 enrichment may be skewed due to the decrease in global
K79me2 levels upon B4N induction (S3 Fig). Other groups have found that H3K79me1 is
highly correlated with actively expressed genes containing low CpG content promoters [16].
While BRD4 and the H3K79 methyltransferase DOT1L do not physically interact, studies in
mixed lineage leukemia have suggested DOT1Lmethylates and establishes a chromatin state
that is permissive for acetylation and BRD4 recruitment [17]. With respect to our results,
genes already decorated with H3K79me1 may be primed for EP300 acetylation and subse-
quent B4N recruitment.
Following the K79 data, we investigated the methyl and acetyl marks enriched by B4N by
focusing on the variant H3.3 27–40 peptide (K27SAPS31TGGVK36KPHR) that spans K27 and
K36. The H3 data described so far in this paper could not distinguish between canonical H3 or
variant H3.3, as the two proteins yield identical peptides at the K18/K23 and K9/K14 positions.
However the alanine and serine substitution at position 31 allows us to use LC-MS to distin-
guish peptides spanning K27 and K36 from the canonical and variant proteins. In fact K27 and
K36 PTM-specific antibodies likely cross-react with both canonical and variant H3 proteins.
In contrast to canonical H3, H3.3 is expressed independently of DNA replication and is
selectively incorporated into active genes by the HIRA histone chaperone [18]. For both canon-
ical and variant H3, di- and tri-methylation at K27 is correlated with gene silencing, while
mono-methylation at K27 is correlated with active expression [19]. Di- and tri-methylation of
K36 is correlated with gene activation and localized to genic regions [20]. Though distinct
enzymes are responsible for modifying these residues, studies in mouse embryonic stem cells
suggested that there is cross-regulation between the enzymes, where knockdown of the K36
methyltransferase Setd2 leads to a reduction in K27 mono-methylation [19].
Our proteomic experiments revealed that B4N does not enrich for H3.3 containing only
K27 methylation or only K36 methylation (Fig 5). This trend is especially pronounced for di-
methylated K27 (K27me2K36un) and tri-methylated K27 (K27me3K36un), where B4N strongly
depletes for both methyl forms. Rather than enriching for individual methyl PTMs, we found
that B4N enriches for combinatorial PTMs such as mono-methylated K27 paired with di-
methylated K36 (K27me1K36me2) as well as with tri-methylated K36 (K27me1K36me3). Notably
K36 tri-methylation is rarely detectedwithout the simultaneous occurrence of K27 mono-
methylation in human cells.
Consistent with previous genomics data [4], our current proteomics data revealed that B4N
enriches for H3.3 containing acetylated K27 paired with unmodifiedK36 (K27acK36un) and
paired with mono-methylated K36 (K27acK36me1). The K27acK36me1 combination is especially
intriguing as this peptide is often below the quantifiable limit in other samples. Additionally
K36 mono-methylation and K27 acetylation generally have distinct metagene profiles, with
K36me1 in genic regions and K27ac in enhancers [21]. MS/MS confirmed that the acetyl
group is on K27 and the methyl group (with the propone group from the derivatization) on
K36 (S9 Fig).
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We observed similar trends of K27/K36 enrichment with canonical H3, albeit with more
subtle enrichment for K27ac (S10 and S11 Figs). Since BRD4short does not significantly enrich
for K27me1K36me2, K27me1K36me3, or K27acK36me1 to the same extent as B4N, the enrichment
of these modified forms by B4N is likely attributed to the NUTmodule. Given the selective
interaction between B4N and EP300/CREBBP, it is possible that K27acK36me1 arises from the
B4N complex acetylating genomic regions already mono-methylated at K36.
It is more difficult though to interpret the B4N enrichment of K27me1K36me2 and
K27me1K36me3. For instance the formation of K27me1K36me3 could signifymono-methylation
at K27 of a pre-existing K36me3 protein or, reciprocally, tri-methylation at K36 of a pre-existing
K27me1 protein. Both the short form of BRD4 and the B4N oncoprotein retain the extra-termi-
nal domain that interacts with the H3K36 methyltransferaseWHSC1L1 (also annotated as
NSD3) [22]. Hence, the enrichment of K36 methylation is unlikely to be accounted by selective
interaction withWHSC1L1.
It is possible that the apparent enrichment for K36 methylation paired with H3K27 mono-
methylation represents a secondary aspect of B4N spreading. In particular, B4N appears to
formmegadomains primarily through the binding of pre-existing histone acetylation that may
be devoid of H3K36 methylation, for instance in regulatory non-coding enhancer regions that
instead contain H3K27 acetylation. This is supported by previous ChIP-seq studies of B4N
induction in 293-TREx cells that revealed B4N initially binds to enhancers before forming
megadomains [4]. As such, we propose the followingmodel for B4N with respect to BRD4short
Fig 5. Quantification of variant H3.3 K27 and K36 modification enrichment. Relative levels of combinatorially modified forms of K27 and K36
methylation and acetylation. Error bar of genomic and BRD4short sample represents standard deviation of 4 replicates. Note the significant enrichment for
K27 mono-methylation paired with K36 di- and tri-methylation by B4N, as well as K27 acetylation paired with K36 mono-methylation.
doi:10.1371/journal.pone.0163820.g005
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(Fig 6). BRD4short binds to acetylated chromatin via its double bromodomains. B4N, similar to
BRD4short, would initially bind to non-genic regions that contain pre-existing acetylation. After
initial binding though, B4N complexes, and in particular its EP300 binding partner, may gener-
ate new acetylations at H3K18 in adjacent chromatin, for instance into genic regions that do
contain pre-existing H3K36 tri-methylation. This spreading could account for the high enrich-
ment of H3K18 acetylation as well as apparent enrichment of K27me1K36me3 by B4N. Further-
more, the initial binding and propagation from active enhancers by B4N complexes could
account for the higher enrichment of H3.3 K27acK36un and K27acK36me1 relative to canonical
H3.1/H3.2, since H3.3-containing nucleosomes are selectively found in these regulatory
regions.
Discussion
The histone code describes how PTMs are linked to gene regulation through the relevant non-
histone factors that form, remove, and recognize PTMs. From our proteomic studies into
how BRD4-NUT binds to chromatin, we uncovered complex histone PTM patterns associated
with the fusion oncoprotein. We believe these combinatorial PTMs arise from the activities of
B4N and its associated enzymes such as EP300. Our data suggest that the B4N complex
Fig 6. Model for ectopic histone PTM activation by the B4N complex. (A) Wild type BRD4 recognizes regions that are already acetylated. (B) B4N
complex binds to regions already acetylated. These regions may also be already marked with H3K79 mono-methylation. With the EP300 binding partner,
the B4N complex targets adjacent chromatin for additional acetylation, for instance at H3K18. This creates additional binding sites for B4N, allowing B4N
to spread farther than wild type BRD4 and potentially into regions containing H3K36 methylation. Wild type BRD4 can also co-localize with B4N as
megadomains are established.
doi:10.1371/journal.pone.0163820.g006
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overrides the pre-existing histone code and forms an epigenetic state corresponding to aberrant
transcription.
Previous sequencing experiments have shown that B4N domains are generally delimited
within topologically associated domains (TADs) [4]. It remains possible that the PTM patterns
we observe are due to B4N complexes aggregating pre-existing PTMs within a given TAD with-
out any de novo PTM conversion. However our previous experiments showed that when B4N
was induced in 293-TREx cells, H3K27ac spreads from localized pre-existing peaks into much
broader regions that tracked with the emergence of B4Nmegadomains [4]. The increase in
H3K27ac over genomic regions previously devoid of acetylation suggests newmodification for-
mation in response to B4N.
A more direct future experiment to determine whether de novo PTM formation and turn-
over is occurringwould be to induce B4N and BRD4short with pulse labeling of isotopically
heavy glucose, which labels new acetyl groups. If our model for PTM generation within B4N
domains were correct, we expect the acetyl labeling efficiency in B4N-associated chromatin rel-
ative to non-associated chromatin to be higher than BRD4short-associated chromatin relative to
non-associated chromatin.
With respect to the dynamics of histone PTM regulation, it is interesting to note that the
rate of histone H4 acetylation turnover in human foreskin fibroblasts is nearly double when
cells are actively proliferating as opposed to when cells are quiescent [23]. As NMC cells
resume proliferation due to oncogene activation, the efficiencyof acetylationmay accelerate
and further facilitate the formation of megadomains. Thus in the treatment of NMCs, it would
be advantageous to block the cycle of aberrant PTM formation either by directly knocking out
B4N itself or using small molecules that selectively inhibit the B4N-dependent interaction with
EP300/CREBBP. Such approaches should minimize off-target effects against wild type BRD4
and could synergistically act with other compounds such as Flavopirodol, which has shown
promising results in inducing cytotoxicity in NMC cells compared to non-NMC controls [24].
One intriguing aspect of NMC is the sequestration of B4N-bound enzymes. Previous experi-
ments have shown that B4N has lower intra-nuclear mobility than wild type BRD4, presum-
ably reflecting the B4N complex being trapped within regions of concentrated histone
acetylation [25]. The titration of B4N components within megadomains could lead to an
imbalance of enzymatic regulation outside of megadomains, potentially resulting in hypo-acet-
ylation. Indeed treatments that administer the lysine deacetylase inhibitor Vorinostat and that
presumably restore the histone acetylation and transcriptional patterns of these non-megado-
main regions have shown promise in treating NMC patients [26]. To clarify the mechanisms of
KAT sequestration, future studies should characterize the histone PTMs in regions outside of
megadomains before and after therapeutic intervention. Though we focused solely on
BRD4-NUT in this report, future research should also determine whether other NMC fusion
proteins, such as BRD3-NUT, NSD3-NUT, and even other BRD4-NUT proteins with different
fusion junctions, enrich for similar modifications [25, 27–29]. Finally, it would be critical to
study resectedNMC patient tissues and perform affinity pulldowns to identify NUT-fusion
protein associatedmodifications.We estimate based on nascent RNA-sequencing that the level
of B4N induced in non-NMC cells is approximately 5-fold higher than endogenous B4N
expressed in NMC cells [4]. Studying the endogenous NUT-fusion protein in NMC tissues
would avoid bait over-expression.
In summary, B4N enriches for chromatin containing multiple acetyl and methyl groups. It
would have been difficult to assay such complex isoforms with conventional antibody-based
approaches. Furthermore it would have been challenging to isolate B4N-bound complexes
with conventional native affinity approaches. The use of formaldehyde and sonication effec-
tively preserves and solubilizes complexes containing DNA, RNA, and protein that could
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otherwise be destabilizedwith MNase digestion and salt extractions. In this respect, Bio-
TAP-XL will be an invaluable method to understand how aberrant regulation of the histone
codemay drive other chromatin-centric diseases.
Supporting Information
S1 Fig. Western Blot of induction of BioTAP-tagged baits in 293-TREx cells.Western Blot
analysis of protein extracts from tetracycline induced 293-TREx that are non-transfected (Lane
1), expressing BioTAP-L3MBTL3 (Lane 2; 100kd expectedmolecular weight), BioTAP-BRD4-
short (Lane 2; 100kd expectedmolecular weight) (Lane 3), and BioTAP-B4N (Lane 4; 220 kd
expectedmolecular weight). PAP detects BioTAP-tagged baits. GAPDH and Ponceau staining
reveal equal loading of extracts.
(TIF)
S2 Fig. Consistency of BioTAP-XL experiments and global non-specific effects of B4N
induction.Recovery of H2A variant peptides across genomic and immunoprecipitated chro-
matin spanning endogenous substitutions at position 16 (serine compared to threonine). Error
bar of genomic sample and BRD4short represents standard deviation of 4 replicates while error
bar of B4N sample represents range of 2 replicates.
(TIF)
S3 Fig. Test for global non-specific effects of B4N induction.Comparison of global histone
PTM levels in 293-TREx cells before and 7 hours after B4N induction. Each point in the plot
represents a PTM. Relative PTM levels were determined as described in the report, where the
area under the peak for each modifiedpeptide was normalized to the sum of all the areas of the
unmodified and modified forms of a given peptide backbone. The relative quantification was
performed for both 0hr and 7hr induction, and the values per PTM at the two timepoints were
log2 transformed and multiplied by -1. Note that, aside from H3K79 di- and tri-methylation,
most PTMs on a genome wide scale do not significantly change upon B4N induction.
(TIF)
S4 Fig. Linear correlation between histone PTM patterns. Pearson’s coefficient r was deter-
mined for the collective relative abundances of histone PTMs in pairwise comparisons between
our samples (genomic input, BRD4short, and B4N). Above the diagonal are scatterplots of each
comparison, with each point representing a histone PTM. For each comparison, we tested the
likelihood that we would have observed the sample correlation if our null hypothesis of r being
0 were true. Thus low p-values suggest a high likelihood that there is a correlation. Statistical
values are shown below the diagonal, where p-values are bolded and the lower and upper 95%
confidence interval for Pearson’s coefficient are shown below. We find that within replicates,
our MS-based PTM quants are tightly correlated. However, the B4N samples are not correlated
(positively or negatively) with either input or BRD4short, suggesting that the B4N-associated
PTM patterns as a whole are highly distinct from input and BRD4short.
(TIF)
S5 Fig. Non-confocal imaging of BRD4short and B4N with H3K18ac. Images of 293-TREx
cells expressing inducible HA-B4N and HA-BRD4short stained with anti-HA (green), which
labels the bait protein, and anti-H3K18ac (red), acquired on non-confocal widefield fluores-
cencemicroscopy. Scale bar represents 10 micrometers.
(TIF)
S6 Fig. Separate layers of confocal imaging of B4N and H3K18ac. Same confocal image as
Fig 3 with separate panels for the green (left, stained for BRD4-NUT bait) and red (right,
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stained for H3K18ac) channels for clarity.
(TIF)
S7 Fig. Quantification of H3 K9, K14 acetylation enrichment.Relative levels of unmodified,
mono-acetylation and di-acetylation of the H3 peptide spanning K9 and K14 in genomic and
immunoprecipitated histones. Error bar of genomic and BRD4short sample represents standard
deviation of 4 replicates. Error bar of B4N sample represents range of 2 replicates. Asterisk
denote significant difference in H3K9K14ac2 levels between input and BRD4short (p< 0.05).
(TIF)
S8 Fig. Quantification of H3 K79 methylation enrichment.Relative levels of unmodified,
mono-methylated and di-methylated H3K79 in genomic and immunoprecipitated histones.
Error bar of genomic and BRD4short sample represents standard deviation of average of 3 repli-
cates. Error bar of B4N sample represents range of 2 replicates. Asterisk denote significant dif-
ference in K79me1 levels between input and BRD4short (p< 0.05).
(TIF)
S9 Fig. MS/MS of variant H3.3 K27acK36me.Annotated tandemmass spectrumof the H3.3
peptide containing K27 acetylation and K36 monomethylation. Numbers above and below
peptide sequence correspond to nominal masses of b and y fragment ions. Boldedmasses indi-
cate those ions annotated from the spectrum.Pr = propone group from derivatization.
(TIF)
S10 Fig. Quantification of canonicalH3.1/H3.2 K27 and K36 PTM levels.Relative levels of
combinatorially modified forms of K27 and K36 methylation and acetylation. Error bar of
genomic and BRD4short sample represents standard deviation of 4 replicates. Note the signifi-
cant enrichment for K27 mono-methylation paired with K36 di- and tri-methylation by B4N.
(TIF)
S11 Fig. MS/MS of canonicalH3.1/H3.2 K27acK36me.Annotated tandemmass spectrumof
the canonical histone H3 peptide containing K27 acetylation and K36 monomethylation.
Numbers above and below peptide sequence correspond to nominal masses of b and y frag-
ment ions. Boldedmasses indicate those ions annotated from the spectrum.Pr = propone
group from derivatization.
(TIF)
S1 Table. Relative quantification of histone PTM levels.
(XLSX)
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